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Levels of endogenous nitric oxide synthase inhibitor asymmetric
dimethylarginine (ADMA) are elevated in chronic kidney disease (CKD) and
may contribute to vascular complications. In this study we tested the
hypothesis that elevated ADMA can be reduced in CKD patients by long-term
administration of low-protein diet (LPD) supplemented with keto amino acids
(KA). In a long-term prospective double blind placebo controlled randomized
trial, we evaluated a total of 120 CKD patients (62/58F) aged 22-76 yrs with
creatinine clearance 22-40mL/min/1.73m2 for a period of 36 months. All
patients were on low-protein diet containing 0.6 protein/kg/IBW/day and 120-
125/kJ/kg/IBW/day. LPD was randomly supplemented with KA at dosage of 100
mg/kg/IBW/day (61 patients, Group I) while 59 patients (Group II) received
placebo. During the study period, glomerular ﬁltration rate (GFR) slightly
decreased (Ccr from 34.2711.6 to 29.979.2 mL/min and 33.5711.6 to
22.2710.4 mL/min in Group I and II, respectively); this however was more
marked in Group II (po0.01). Fat in muscle measured by MR spectroscopy
(MRS, m.tibialis anterior) signiﬁcantly decreased in Group I and was linked to
reduced volume of visceral fat measured by MRI (po0.01). Reduction of fat in
Group II was not signiﬁcant. In Group I, there was a signiﬁcant decrease in the
plasma level of ADMA (from 2.470.4 to 1.270.3 mmol/L, po0.01), but ADMA
remained unchanged in Group II. A further remarkable ﬁnding was reduction in
the plasma concentration of pentosidine (from 4867168 to 3257127 mg/L,
po0.01) and decrease of proteinuria (from 3.772.20 to 1.671.2 g/24hrs,
po0.01) in Group I. Plasma adiponectin (ADPN) in Group I rose (po0.01).
Analysis of lipid spectrum revealed a mild yet signiﬁcant decrease in total
cholesterol and LPD-cholesterol (po0.01), more pronounced in Group I. In
Group I, there was a decrease in plasma triglycerides (from 3.871.5 down to
2.370.5 mmol/L, po0.01), whereas glycated hemoglobin (HbAc1) decreased
from 7.071.3 to 4.170.9 %, (po0.01) nIn conclusion,comparing to placebo
group long term co-administration of LPD and KA in CKD patients led to
decrease of ADMA,fat in muscle and visceral body fat, and proteinuria.
Concomitant decreases of glycated haemoglobin, LDL-c and pentosidine may
also contribute to the delay in progression of renal failure and decrease of
cardiovascular risk factors..The study was supported by Research Project MZO
00023001 awarded by Ministry of Health of the Czech Republic
http://dx.doi.org/10.1016/j.krcp.2012.04.577254
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Insulin resistance is common in dialyzed patients and is associated with
increased mortality and protein-energy wasting. The aim of this study was to
investigate the effect of pioglitazone (PIO), a powerful insulin sensitizer, on
insulin sensitivity, body composition and adipose tissue metabolism, in
dialyzed patients. A double blind randomized cross-over study was performed
in non diabetic dialysis patients. Each patient followed 2 treatment phases of
16 weeks, starting either with oral PIO 45 mg/d or placebo (PL), and then
switched to the other phase. At the end of each phase, patients underwent
hyperinsulinemic euglycemic clamps, dual energy X-ray absorptiometry, an
abdominal CT, and extensive plasma biochemical analysis. Twelve patients
including 8 HD (59.674.4 y) and 4 PD patients (43.573.6 y) were recruited.
Nine patients completed both phases and 3 patients dropped out (renal
transplantation/2 HD and peritonitis/1 PD). PIO was safe and well tolerated.
Under PIO, insulin sensitivity improved, as assessed by increased total glucose
disposal rate (1.9870.24 for PIO versus 1.5870.12 umol/kg/min for PL,
po0.05), and reduced glucose endogenous hepatic production. PIO did not
affect post-dialysis bodyweight, total fat and lean body mass, but signiﬁcantlyreduced visceral adipose tissue (VAT) area and the VAT/SAT (subcutaneous
adipose tissue) ratio. HDL-cholesterol signiﬁcantly increased. PIO decreased
CRP (3.9671.44 mg/l vs 7.8872.56, po0.05), plasma leptin, and
dramatically reduced leptin/adiponectin ratio. Glycerol turnover, circulating
glycerol and non esteriﬁed fatty acids were paradoxically increased. In
conclusion, the improvement in insulin sensitivity by PIO, in non diabetic
dialyzed patients, was associated with favorable metabolic effects, reduction
in inﬂammation and body fat redistribution. The stimulation of systemic
lipolysis was a surprising ﬁnding which may reﬂect adipose tissue remodeling
and/or a paradoxical lypolitic effect of PIO in this population.
http://dx.doi.org/10.1016/j.krcp.2012.04.578255
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Haemodialysis patients may have low albumin levels due to a cascade of
factors, including inﬂammation and reduced dietary intake. Albumin is
commonly used in clinical settings by dieticians as part of a comprehensive
nutritional assessment. Presently many dietetic practitioners use
interchangeably pre-dialysis and post-dialysis biochemical measurements for
albumin. The aim of this study was to quantify the difference between pre-
dialysis and post-dialysis serum albumin measurement and its relationship to
intra-dialytic weight gain. Fourty-six stable (21 Australian indigenous, 25
non-indigenous) haemodialysis patients were enrolled in a three month
cross-sectional study. During the study patients underwent routine
haemodialysis treatment and biochemical tests. Weight and biochemical
measurements were collected pre and post dialysis on the ﬁrst Tuesday or
Wednesday of each month. A patient generated subjective global assessment
(PG-SGA) was conducted in the thirdmonth of the study. The incidence of low
albumin levels (o35g/L) was 56% (n¼26) when serum albumin was
measured pre-dialysis, this was reduced to 30% (n¼14) when measured post-
dialysis. Analysis of serum albumin found a 2.6g/L (CI 1.7-3.5) difference in
concentration between pre and post dialysis measurements (p¼0.000), with
serum albumin less concentrated in pre-dialysis blood samples. Intra-dialytic
weight gain (2.0kg, CI 1.7-2.3) correlated with the change in serum albumin
(r¼ 0.464, p¼0.001). Intra-dialytic weight gain and the difference between
pre and post dialysis serum albumin was greater in Australian indigenous
patients than in non-indigenous patients. PG-SGA score was more strongly
correlated with post-dialysis than pre-dialysis serum albumin (r¼0.430,
p¼0.003; r¼0.389, p¼0.008 respectively).This study indicates that
measurement of serum albumin should be undertaken post-dialysis when
using the measurement as part of a nutritional assessment. Pre-dialysis serum
albumin measurement may falsely indicate poor nutritional status, and
should be followed with a post-dialysis measurement to conﬁrm ﬁnding.
http://dx.doi.org/10.1016/j.krcp.2012.04.579256
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Indigenous Australians have an increased incidence of kidney disease
and decreased survival on hemodialysis. The aim of this study was to
investigate whether differences in nutritional status exist between
indigenous and non-indigenous patients undergoing maintenance
hemodialysis in South Australia.
Seventy-two (22 Australian indigenous, 50 non-indigenous) stable
hemodialysis patients were enrolled in a three month cross-sectional
study. During the study patients underwent routine hemodialysis
treatment and biochemical tests. Weight and biochemical measurements
were collected pre and post dialysis on the ﬁrst Tuesday or Wednesday of
each month. A patient generated subjective global assessment (PG-SGA)
